Ecallantide
Mechanism :
Ecallantide is a recombinant protein which inhibits the conversion of high molecular weight kininogen to bradykinin by selectively and reversibly inhibiting plasma kallikrein.
Indication :
- Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years and older.
Contraindications :
Hypersensitivity to ecallantide or any component of the formulation.
Dosing :
SC: 30 mg. If attack persists, may repeat an additional 30 mg within 24 hours.
Adverse Effect :
Headache, nausea, fatigue, antibody development, skin rash, pruritus, urticarial, vomiting, anaphylaxis, injection site reactions, URTI, fever.
Interaction :
No known significant interactions.
Hepatic Dose :
No dosage adjustments are recommended.